Formula for success as Martyn Greenacre joins board
This article was originally published in Scrip
Oncology drug development company Formula Pharmaceuticals has appointed Martyn Greenacre to its board of directors. Previously, Mr Greenacre served as chair of BMP Sunstone Corporation before its acquisition by Sanofi-Aventis, CEO and a director of Delsys Pharmaceutical Corporation, and president and CEO of Zynaxis.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.